AstraZeneca PLC (AZN)vsSepterna, Inc. Common Stock (SEPN)
AZN
AstraZeneca PLC
$185.95
-0.83%
HEALTHCARE · Cap: $282.69B
SEPN
Septerna, Inc. Common Stock
$31.15
-0.70%
HEALTHCARE · Cap: $1.36B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 83547% more annual revenue ($60.44B vs $72.25M). AZN leads profitability with a 17.2% profit margin vs -49.9%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SEPN
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for SEPN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 12011.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -9.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SEPN
The strongest argument for SEPN centers on Revenue Growth, Debt/Equity. Revenue growth of 12011.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SEPN
The primary concerns for SEPN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while SEPN is a hypergrowth play — different risk/reward profiles.
SEPN is growing revenue faster at 12011.0% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 31/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Septerna, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Septerna, Inc. is a pioneering biotechnology firm dedicated to advancing transformative therapeutics through selective protein modulation. The company harnesses proprietary technologies and unparalleled scientific expertise to develop a promising pipeline of next-generation drug candidates aimed at addressing unmet medical needs across various disease areas. With a strong emphasis on research and development, Septerna is strategically positioned for growth, presenting a compelling investment opportunity for institutional investors in the rapidly evolving biopharmaceutical landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?